Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492972 · ClinicalTrials.gov registry record · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Proton Collaborative Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 192
- Enrollment target
- 4
- Study locations
NCT01492972: Recruiting Phase 3 study of Prostate Cancer, sponsored by Proton Collaborative Group.
NCT01492972 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by Proton Collaborative Group. The registered enrollment target is 192 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (68% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01492972, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by Proton Collaborative Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 192 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not completely understood. This study will compare the use of hypofraction proton therapy (28 treatments) alone to proton therapy with androgen suppression therapy.
Conditions Studied
Interventions
- RADIATION Radiation
- DRUG Androgen Suppression Therapy
Study Locations (4)
Arizona
- Mayo Clinic - Scottsdale
Illinois
- Northwestern Medicine Chicago Proton Center - Warrenville
Oklahoma
- Oklahoma Proton Center - Oklahoma City
Virginia
- Hampton University Proton Therapy Institute - Hampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492972
The ClinicalTrials.gov registry entry for NCT01492972 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Proton Collaborative Group, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation is the first listed.
NCT01492972 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Illinois, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT01492972 about?
NCT01492972 is a clinical study titled "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer". The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The benefit of the combination with androgen suppression is not...
What is the current status of trial NCT01492972?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 192 participants. The study started on 2012-01.
What conditions does trial NCT01492972 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01492972?
The interventions under investigation include: Radiation (RADIATION), Androgen Suppression Therapy (DRUG).
Who is sponsoring clinical trial NCT01492972?
This trial is sponsored by Proton Collaborative Group, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01492972 being conducted?
This trial has 4 study locations across Arizona, Illinois, Oklahoma, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.